|
|||||
|
|
| Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter
|
| Ticker | Owner | Relationship | Date | Transaction | Cost |
#Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 25 '25 | Sale | 14.40 | 6,468 | 93,160 | 77,540 | Feb 27 04:28 PM |
| TCMD | Burns Kristie | Officer | Feb 25 '25 | Proposed Sale | 14.40 | 6,468 | 93,160 | Feb 25 07:15 PM | |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 24 '25 | Sale | 14.65 | 4,830 | 70,753 | 84,008 | Feb 24 06:23 PM |
| TCMD | Burns Kristie | Officer | Feb 24 '25 | Proposed Sale | 14.65 | 4,830 | 70,753 | Feb 24 05:12 PM | |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | May 06 '24 | Sale | 14.37 | 815 | 11,713 | 62,574 | May 08 05:23 PM |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 27 '24 | Sale | 15.58 | 1,091 | 17,001 | 63,632 | Feb 29 08:43 PM |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 29 '24 | Sale | 15.25 | 243 | 3,706 | 63,389 | Feb 29 08:43 PM |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 23 '24 | Sale | 14.80 | 2,249 | 33,278 | 53,765 | Feb 27 09:12 PM |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 26 '24 | Sale | 15.90 | 2,015 | 32,049 | 63,512 | Feb 27 09:12 PM |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | May 08 '23 | Sale | 18.65 | 786 | 14,659 | 36,562 | May 10 04:18 PM |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 27 '23 | Sale | 15.39 | 2,162 | 33,276 | 37,483 | Feb 28 08:34 PM |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 28 '23 | Sale | 14.58 | 135 | 1,968 | 37,348 | Feb 28 08:34 PM |
| TCMD | Burns Kristie | Sr. VP Mktg & Clinical Affairs | May 06 '22 | Sale | 13.04 | 999 | 13,023 | 21,959 | May 10 04:32 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite